| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Interim results from the CARE PMR study support the use of ultra-low-field MRI as a triage tool for monitoring patients on amyloid-targeting therapies.
Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced promising early results from the CARE PMR (Capturing ARIA Risk Equitably with Portable MR) study presented at the 2025 Alzheimer's Association International Conference in Toronto, Canada.
Researchers from the Benzinger Lab at Washington University School of Medicine in St. Louis reported interim results from 31 Alzheimer's patients undergoing Lecanemab therapy. Participants were scanned using the Swoop® system within one week of their clinical high-field MRI scans, as part of the safety monitoring protocol required by the FDA when it approved Lecanemab.
The Swoop® system achieved 100% sensitivity in detecting mild to moderate ARIA-E, a condition marked by cerebral edema. Researchers note that while ultra-low-field MRI is promising as a triage tool to screen for ARIA-E, high-field MRI may remain necessary for comprehensive evaluation in some cases.
Posted In: HYPR
